• / Free eNewsletters & Magazine
  • / My Account
Home>Leader in Genomic Sequencing Illuminates the Way

Leader in Genomic Sequencing Illuminates the Way

Morningstar Articles

Wed, 14 Jan 2015

Continued technology advancements and market expansion support Illumina's narrow moat.

Related Videos

  1. 3 Big Moat Rating Changes From 2014

    Competitive advantages have improved for Mead Johnson, while De La Rue's moat was downgraded to narrow and POSCO was deemed a no-moat company.

  2. Weekly Wrap: What's Next for Chipotle

    The fast-casual chain is moving on after a food safety scare, but we think it could be an up and down year for the firm. Plus, positive reaction for Illumina , and we're bearish on steel.

  3. Will Life Sciences Firms Fall Off the Fiscal Cliff?

    Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.

  4. Peters: Dividend Outlook for 2015

    Repeating a stellar 2014 will be tough for REITs and utilities, while some higher-yielding multinational firms are much more attractive today, says the Morningstar DividendInvestor editor.

©2017 Morningstar Advisor. All right reserved.